Cardilol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardilol

Property Description
Active ingredient Carvedilol (INN)
Form Tablets and Capsules (Oral)
Pharmacological class Combined Alpha- and Beta-Adrenoreceptor Blocker
General purpose Reduces strain and workload on the cardiovascular system
Origin Synthetic

What Type of Medication is Cardilol?

Cardilol, with the active ingredient Carvedilol, is a prescription-only, synthetic cardiovascular drug. It is scientifically recognized as a specialized type of Alpha and Beta blocking agent. This substance holds the specific designation of a dual alpha1 and beta antagonist, which fundamentally differentiates it from older, single-action beta-blockers. Its core function is as an antihypertensive agent. Carvedilol works to both decrease heart rate and relax blood vessels, which serves to manage cardiovascular demand.

Understanding the Composition and Available Forms

The medication contains Carvedilol as a single-ingredient product designed for oral administration. The chemical structure of Carvedilol is a racemic mixture containing two distinct chemical forms: the S(–) and R(+) enantiomers. The presence of both forms is essential, as the S(–) enantiomer provides the primary beta-blocking action while both contribute to the alpha1-blocking action. It is manufactured in various dosage form variants, primarily immediate-release tablets and extended-release capsules. The capsule variant, such as Coreg CR or its generics, offers a pharmacokinetic feature of consistent, long-acting delivery.

What is the General Purpose of Cardilol?

The general therapeutic purpose of Cardilol is to comprehensively decrease the physical strain and workload placed upon the cardiovascular system in adult patients. It achieves this by the concurrent application of two key physiological actions: regulating the heart’s rhythm and promoting peripheral vasodilating effects. By slowing the heart rate and actively relaxing the smooth muscles of the blood vessels, the medication effectively reduces peripheral vascular resistance, allowing the heart to pump blood more efficiently. This dual action functions to stabilize the circulatory system by reducing pressure.

What side effects are possible with Cardilol?

Possible Side Effects and Safety Information

The safety profile for carvedilol (Cardilol) is established by authoritative governmental regulatory documents, which categorize adverse reactions by frequency and type.

Frequency-Classified Adverse Reactions

The most frequent side effects, listed as Very Common (occurring in ge 10% of patients in some studies), are typically cardiovascular or related to general well-being:

  • Dizziness
  • Fatigue/Asthenia
  • Hypotension (low blood pressure)
  • Bradycardia (slow heart rate)

Common adverse reactions (occurring in ge 1% to <10% of patients) include weight gain, fluid retention/edema, headache, nausea, diarrhea, and exacerbation of pre-existing conditions like asthma or peripheral circulatory disorders.

Serious Adverse Reactions and Safety Restrictions

Regulatory agencies document the potential for severe adverse reactions. These include the sudden and severe worsening of heart failure, cardiogenic shock, and the development of Second- or Third-degree Atrioventricular (AV) Block.

Carvedilol is strictly contraindicated and should not be used in the following circumstances:

  • Severe hepatic impairment (severe liver problems).
  • Severe bradycardia or hypotension.
  • Cardiogenic shock or decompensated heart failure requiring intravenous (IV) treatment.
  • Patients with bronchial asthma or related bronchospastic conditions.

Population and Exposure Considerations

The official labeling notes that effects like dizziness or syncope are most likely to occur during the initiation of treatment or following a dose increase. Additionally, abrupt discontinuation of the medicine, particularly in patients with coronary artery disease, may lead to serious cardiac events; therefore, cessation must be gradual.

Patients with diabetes require close glucose monitoring, as carvedilol may mask the symptoms of low blood sugar (hypoglycemia). Geriatric patients may also have higher plasma concentrations, requiring careful assessment.

Overdose and Emergency Response

The ingestion of Cardilol (Carvedilol) beyond prescribed limits is classified in regulatory documents as potentially leading to severe and life-threatening toxicity, with primary effects on the cardiovascular and central nervous systems. No specific antidote is officially known for reversing all effects; management is strictly symptomatic and supportive.

Documented Overdose Manifestations

Official labeling describes several clinical signs and symptoms that may manifest in an overdose situation:

  • Cardiovascular: Bradycardia (slow heartbeat), severe Hypotension (low blood pressure), Cardiac insufficiency, Cardiogenic shock, and Syncope (fainting).
  • Neurological: Lapses of consciousness, Dizziness, and Generalized seizures (convulsions).
  • Respiratory: Bronchospasm and difficulty breathing.

When Immediate Medical Help is Required

Regulatory guidance mandates that immediate medical attention be sought right away for suspected overdose. Contact emergency services or a Poison Control Center immediately if the affected individual has:

  • Collapsed or can't be awakened (loss of consciousness).
  • Had a seizure.
  • Has trouble breathing.

Official Supportive Measures

Management procedures described in official documents include the administration of intravenous Atropine for excessive bradycardia or Glucagon and Sympathomimetics to counteract profound cardiac depression. Due to potential prolonged effects, continuous observation, including ECG monitoring and vital signs checks, is often required.

Therapeutic Uses of Cardilol

What Cardilol Treats: Main Uses and Benefits

Cardilol is used for the treatment of mild-to-severe chronic heart failure to support long-term stability and may assist in managing situations requiring acute support. This medication is commonly used to help with groups of symptoms that may become intense or disruptive, particularly fatigue, generalized weakness, and reduced exercise tolerance which stem from symptoms related to the heart's functional stress.

The medication is also commonly used for managing Essential Hypertension (high blood pressure) and for post-heart attack stabilization in patients with left ventricular dysfunction. By easing the overall symptom burden, this therapy may assist patients with managing long-term cardiovascular risks. It is often applied during phases when symptoms become more noticeable to support general well-being and stability. The medication helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: It is commonly used to help with symptoms related to Reduced Exercise Tolerance.

Eligibility and Restrictions for Use

Eligibility for Cardilol Use

Cardilol (Carvedilol) is officially approved for use in adult patients (18 years and older) with its indicated cardiovascular conditions. The official regulatory labeling strictly defines the populations who must not use the medicine (contraindications) and those for whom use is restricted or conditional.

Absolute Contraindications

Cardilol is formally prohibited for patients with certain pre-existing conditions, including:

  • Severe Hepatic Impairment (severe liver disease).
  • Bronchial Asthma or related severe bronchospastic conditions.
  • Cardiogenic Shock or decompensated heart failure requiring intravenous circulation support.
  • Severe heart rhythm disorders such as Second- or Third-Degree AV Block or Sick Sinus Syndrome (unless a permanent pacemaker is in place).
  • Severe Bradycardia or Severe Hypotension.

Population and Condition Restrictions

Population / Condition Regulatory Eligibility Status
Pediatric Population (<18) Use not established; safety and efficacy have not been determined.
Pregnancy Restricted; to be used only if the potential benefit justifies the potential risk to the fetus.
Breastfeeding Mothers Not recommended; it is unknown if the drug passes into human milk.
Renal Insufficiency Conditional; caution is advised, and monitoring of renal function may be necessary.
Diabetes Mellitus Conditional; use with caution, as it may mask symptoms of hypoglycemia or worsen hyperglycemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation identifies specific patterns through which Cardilol (Carvedilol) interacts with other medicinal products and substances, categorized by the mechanism of action or the resultant effect on drug concentrations or patient physiology.

Documented Pharmacokinetic Interference

The most significant documented pharmacokinetic interactions involve the CYP enzyme system. Co-administration with the CYP inducer Rifampin is documented to reduce Cardilol's plasma exposure ( AUC and C max) by approximately 70%. Conversely, the CYP inhibitor Cimetidine increases Cardilol exposure ( AUC) by 30%. Additionally, Cardilol is officially noted to be an inhibitor of P-glycoprotein ( P-gp), resulting in an increase in the plasma concentrations of co-administered drugs like Cyclosporine.

Pharmacodynamic and Substance Interactions

Additive pharmacodynamic effects are documented with agents that slow the heart rate or lower blood pressure. The use of Cardilol with Digitalis Glycosides ( Digoxin) increases the risk of bradycardia and may increase Digoxin concentrations. Co-administration with non-dihydropyridine Ca^2+ channel blockers, such as Verapamil or Diltiazem, carries a risk of AV conduction disorders. The official labeling specifies that Extended-release capsules must be taken with food, which slows the rate of absorption and is documented to minimize the risk of orthostatic hypotension.

Mechanism of Action

How Cardilol Works

Cardilol functions via three distinct pharmacodynamic domains to modulate cardiovascular activity. Its core mechanism is a dual antagonism, blocking beta1/beta2 adrenergic receptors in the heart and alpha1 receptors in the peripheral vasculature. This blockade reduces the stimulatory effect of the Sympathetic Nervous System (SNS) on cardiac tissues, which reduces the rate and force of heart contractions (negative chronotropy and inotropy), resulting in decreased myocardial energy demand.

Simultaneously, the antagonism of alpha1-adrenergic receptors prevents the contraction of vascular smooth muscle, causing blood vessels to relax and widen. This action reduces the physical resistance, or afterload, that the heart must pump against, thus reducing the physical strain on the circulatory system.

Separately, Cardilol contains structural features that enable it to act as an antioxidant, limiting the destructive effects of oxygen free radicals on myocardial cells. This non-receptor activity provides protection against cellular stress, which complements the hemodynamic effects.

Dosage and Administration Information

Official Administration Guidelines for Carvedilol

Carvedilol, an oral medication, must be taken with food to slow absorption and minimize the risk of orthostatic effects. Dosage administration differs based on the formulation: immediate-release tablets are taken twice daily, while extended-release capsules are taken once daily.


Dosing and Titration Protocol

Dosage must be individualized and closely monitored by a healthcare provider during up-titration.

Indication Initial Dose (Immediate-Release) Titration Interval Maximum Daily Dose (Typical)
Heart Failure 3.125 mg twice daily At least 2 weeks 50 mg (for patients > 85 kg)
Hypertension 6.25 mg twice daily 7 to 14 days 50 mg total daily dose

Special Administration and Preparation

  • Extended-Release Capsules: These must be swallowed whole and should not be crushed, chewed, or divided. If unable to swallow, the capsules may be carefully opened and the contents sprinkled over a spoonful of cool or room-temperature applesauce and the mixture consumed immediately.
  • Missed Dose: If a dose is missed, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular schedule resumed. Do not take a double dose.
  • Discontinuation: Therapy must not be stopped abruptly. The dose should be slowly lowered over a period of 1 to 2 weeks as instructed by a healthcare provider to prevent serious cardiovascular events.

Recent Clinical Evidence

Cardilol: Recent Clinical Evidence

Research regarding Cardilol (Carvedilol) primarily centers on its effect on chronic heart failure (CHF) and left ventricular function following a heart attack.

Clinical Efficacy and Long-Term Outcomes

Multiple randomized controlled trials (RCTs) have assessed the compound's effect when added to existing standard therapy (such as ACE inhibitors and diuretics) in patients with mild to moderate CHF.

  • Mortality and Hospitalization: Long-term studies observed a dose-related reduction in the risk of all-cause mortality and heart failure-related hospitalization rates compared to a placebo group. This effect was demonstrated across various patient populations with systolic dysfunction.
  • Left Ventricular Ejection Fraction (LVEF): Research consistently recorded improvements in LVEF, a key measure of the heart's pumping ability, across different dosage groups over the study period. Improvements were also associated with changes in symptoms and functional class status.

Functional and Symptom Outcomes

Studies also evaluated how Cardilol administration related to physical function and symptoms.

  • Symptom Status: Physician and patient global assessments recorded a greater frequency of symptomatic change in the Cardilol group compared to placebo, particularly concerning a lessening of heart failure symptoms.
  • Exercise Tolerance: Findings concerning changes in submaximal exercise duration, such as the 6-minute walk distance, were mixed or showed limited change when compared to the placebo group. The benefit observed in LVEF was generally more pronounced than the functional benefit measured by exercise capacity.

Tolerability and Study Design

  • Study Tolerability: Cardilol was generally found to be well-tolerated in the primary heart failure trials. Some patients required dose titration (gradual increases) or adjustment due to events like dizziness or hypotension, which are common in this class of medication.
  • Dose Response: Trials were specifically designed to examine if increasing the dose of Cardilol was associated with a greater magnitude of observed change in LVEF and long-term outcomes, which research supported.

Frequently Asked Questions (FAQ)

Common questions about Cardilol (FAQ)

Q: What is the difference between Cardilol and other similar 'beta-blocker' medicines?

Cardilol (Carvedilol) is scientifically known as a dual alpha (alpha1) and beta (beta) antagonist. This means it blocks two types of receptors in the body, which is what differentiates it from single-action beta-blockers. This dual mechanism contributes to its effects on both the heart rate and blood vessel relaxation, according to official product information.

Q: Do you take Cardilol long-term or short-term?

Cardilol is used for the management of chronic conditions such as heart failure and hypertension. Regulatory documents emphasize that therapy should not be stopped abruptly and often involves a gradual reduction of the dose, a common precaution for medications used consistently over an extended period.

Q: How quickly should someone expect Cardilol to start working?

Initial effects, such as its blood vessel-relaxing activity, have been reported to occur within about 30 minutes of administration. However, official clinical data indicates that the full therapeutic effect on blood pressure may take longer, typically developing over a period of 7 to 14 days.

Q: Are there any major diet changes to consider while taking Cardilol?

The official product labeling specifies that Cardilol should be taken with food. This condition helps to slow the rate of absorption of the medicine, which may minimize the risk of dizziness or lightheadedness, particularly when standing up quickly.

Q: Can older adults safely use Cardilol?

Cardilol is approved for adult use. However, use in geriatric patients is conditional and requires careful assessment because this population may experience higher plasma concentrations of the drug, according to regulatory sources.

Q: What are the most common reasons a doctor might decide to stop Cardilol?

Regulatory documents list conditions that would prohibit the use of the medicine (contraindications) or adverse events that may lead to discontinuation. These include severe liver problems, asthma, or the development of severe symptoms like significantly low blood pressure or a very slow heart rate (bradycardia).

Q: Is Cardilol used to prevent future heart issues?

Clinical studies described in official documentation are associated with a reduction in the risk of certain future cardiac events. When prescribed following a heart attack, the drug has been observed to reduce the risk of death and subsequent non-fatal heart attacks.

Q: What is the difference between immediate-release and extended-release versions of Cardilol?

Official information states that the key differences relate to the dosing schedule and the rate of drug delivery. The immediate-release tablet is typically taken twice daily, while the extended-release capsule is taken once daily, providing consistent receptor-blocking effects over a full 24-hour period.

Q: Can taking Cardilol cause cold hands and feet?

Official adverse reaction reports indicate that Cardilol may cause the exacerbation of pre-existing peripheral circulatory disorders. This effect can lead to symptoms of reduced blood flow, such as coldness in the hands and feet.

Q: Can Cardilol affect a person's sleep pattern?

Official safety data has reported that Cardilol can be associated with certain sleep disorders. These include both insomnia (difficulty sleeping) and somnolence (unusual drowsiness or sleepiness), which are categorized as uncommon side effects.

Q: Can Cardilol be taken with common over-the-counter pain relievers?

Regulatory documents note the potential for an interaction when Cardilol is used with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which include common pain relievers. NSAIDs may lessen the effectiveness of Cardilol in lowering blood pressure and could increase the risk of worsening heart failure.

Q: Are there any foods or supplements that interact with Cardilol?

The drug is metabolized by specific enzymes in the body (the CYP450 system). Official information indicates that certain herbal products or supplements that affect these enzymes, such as St. John's Wort, could potentially alter the concentration of Cardilol in the bloodstream.

Q: Is Cardilol ever used for treating anxiety or tremors?

Cardilol is officially approved for cardiovascular conditions like heart failure and hypertension. Official label information notes that the beta-blocking effect may mask the physical signs of tremors associated with low blood sugar (hypoglycemia), which is a consideration during use.

Q: Can Cardilol change laboratory test results?

Yes, official labeling notes that certain laboratory parameters may be affected by the medication. For example, blood glucose levels, cholesterol levels, and liver function test results may require monitoring during the course of treatment.

Q: Is Cardilol available as a generic medicine?

Yes, Cardilol is the brand name for the active ingredient carvedilol, which is available as an FDA-approved generic medication. The generic version is an approved equivalent to the brand-name product.

Q: What is the typical duration of action for Cardilol in the body?

The drug's activity can be measured by its average elimination half-life, which is the time it takes for half of the dose to be cleared from the body. For Cardilol, the elimination half-life following oral administration is approximately 7 to 10 hours.

Q: Can Cardilol cause changes in mood?

Yes, official adverse reaction reports have included changes in mood, such as depression or depressed mood. These are listed as reported side effects that occurred during clinical trials for the medication.

Q: Are there any specific lifestyle changes that are recommended when taking Cardilol?

Official safety warnings indicate that individuals should be cautious about activities requiring mental alertness, such as driving or operating heavy machinery, until they understand how the medicine affects them, especially due to the risk of dizziness.

Q: Can Cardilol affect sexual function?

Official adverse event reporting has included issues affecting sexual function. These include reports of decreased interest in sexual intercourse, erectile dysfunction, or a change in sexual performance.

Q: Does Cardilol interact with alcohol?

Official patient information explicitly states that consuming alcohol while taking Cardilol can increase the risk of side effects. This combination may lead to additive effects, increasing the chance of dizziness, lightheadedness, and fainting.

Q: What should be done if a user experiences an allergic reaction to Cardilol?

Regulatory warnings describe the signs of a serious allergic reaction, such as developing a rash, hives, or swelling of the face or throat. If these symptoms occur, the official documentation advises seeking medical attention immediately.

Q: Are there specific symptoms that signal a potential serious interaction with Cardilol?

Official regulatory warnings list certain symptoms that may indicate a serious interaction or issue, such as severe dizziness, fainting, a very slow heartbeat (severe bradycardia), or sudden shortness of breath or swelling, which could signal worsening heart failure.

Q: Does Cardilol have a boxed warning in official documents?

Yes, the official labeling for Cardilol (Carvedilol) is required to include a U.S. FDA Boxed Warning. This warning highlights the risk associated with abruptly stopping the medication, which can lead to a worsening of chest pain (angina) or even a heart attack.

Q: What research is currently happening related to Cardilol?

Official government databases show that research continues to be conducted on Cardilol. These ongoing studies include bioequivalence trials, which ensure that generic versions are equivalent to the brand, as well as clinical trials in specific patient populations.

Q: How long after taking Cardilol should a person avoid driving if they feel dizzy?

Official safety warnings indicate that individuals should be cautious about activities like driving or operating machinery when symptoms like dizziness or lightheadedness are most likely to occur. This period is often noted as being within the first hour after taking a dose or immediately following a dose increase.

How should Cardilol be stored and disposed of?

Cardilol (Carvedilol) must be stored at Controlled Room Temperature, which is officially specified as 20^circ,C to 25^circ,C (68^circ,F to 77^circ,F), with a maximum limit below 30^circ,C (86^circ,F). The medication must be protected from moisture and kept in a tightly closed, light-resistant container to prevent degradation and maintain stability.

Storage Requirement Condition
Temperature Controlled Room Temperature
Environment Protect from light and moisture
Container Keep tightly closed
Child Safety Keep out of the reach of children

All expired or unused Cardilol must be safely disposed of and handled in accordance with local requirements for pharmaceutical waste. Disposal instructions advise returning unused prescription drugs to a local pharmacist for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardilol found in:

A-Z Index: